A number of investment brokers have recently updated their price targets on shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH). According to the latest broker reports outstanding on Monday 9th of May, 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts “neutral”, 0 analysts “sell” and 0 analysts “strong sell”.

Most recent broker ratings

02/19/2016 – Wells Fargo began new coverage on Amphastar Pharmaceuticals, Inc. giving the company a “outperform” rating.

01/19/2016 – Amphastar Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Jefferies. They now have a USD 17 price target on the stock.

06/19/2015 – Amphastar Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Needham & Company. They now have a USD 21 price target on the stock.

06/04/2015 – Amphastar Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Raymond James. They now have a USD 23 price target on the stock.

05/14/2015 – Amphastar Pharmaceuticals, Inc. had its “outperform” rating reiterated by analysts at BMO Capital Markets. They now have a USD 20 price target on the stock.

05/01/2015 – Amphastar Pharmaceuticals, Inc. was upgraded to “hold” by analysts at Zacks.

03/25/2015 – Amphastar Pharmaceuticals, Inc. had its “overweight” rating reiterated by analysts at Piper Jaffray. They now have a USD 19 price target on the stock.

The share price of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) was down -0.85% during the last day of trading, with a day high of 12.05. 213546 shares were traded during the last session.

The stock’s 50 day moving average is 12.44 and its 200 day moving average is 12.63. The stock’s market capitalization is 527.62M. Amphastar Pharmaceuticals, Inc. has a 52-week low of 10.50 and a 52-week high of 18.30.

View other investors thoughts on Amphastar Pharmaceuticals, Inc. with our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.